Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021
| Autor: | Monique Nijhuis, Steven G. Deeks, Richard Dunham, Marein A. W. P. de Jong, Marein de Jong, Thanyawee Puthanakit, Mirko Paiardini, Santiago Perez Patrigeon, Krista L. Dong, Jan van Lunzen, Luke Jasenosky, Jessica Salzwedel, Simon Collins, Katharine J. Bar, Frank Mardarelli, Jeffrey T. Safrit, Jeremy Sugarman, Alex Schneider, Nancie M. Archin, Zaza M. Ndhlovu, Joel N. Blankson, Zabrina L. Brumme, Hans-Peter Kiem, Gaerolwe Masheto, Beatriz Mothe, Karine Dubé, Katherine Luzuriaga, Jennifer Power, Sarah Fidler, Richard Jefferys, Fu Sheng Wang, Jeff Taylor, Kumitaa Theva Das, Boro Dropulic, Kai Deng, Devi SenGupta, Sharon Lewin, Marina Caskey, Susana T. Valente, Siegfried Schwarze, Nicolas Chomont, R. Brad Jones, Ole S. Søgaard, Paula M. Cannon, Olivier Lambotte, Edward Nelson Kankaka, Gabriela Turk, Christina Antoniadi, Udom Likhitwonnawut, Caroline T. Tiemessen, Pablo Tebas, Rosanne Lamplough, Cissy Kityo, Fernanda Heloise Côrtes, Melannie Ott, Rose Nabatanzi, Oguzhan Latif Nuh, Mitch Matoga, Linos Vandekerckhove, J. Victor Garcia, Thumbi Ndung'u, Bonnie J. Howell, Aurelio Orta-Resendiz, Ricardo Sobhie Diaz, Michael Louella, Ann Chahroudi, Deborah Persaud, Stephan Dressler, Josephine Nabukenya, Sharon R Lewin |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Host genome business.industry Research areas Human immunodeficiency virus (HIV) General Medicine medicine.disease_cause medicine.disease Priority areas Antiretroviral therapy General Biochemistry Genetics and Molecular Biology Clinical trial Acquired immunodeficiency syndrome (AIDS) Infected cell Medicine business Intensive care medicine |
| Zdroj: | Nature Medicine. 27:2085-2098 |
| ISSN: | 1546-170X 1078-8956 |
| DOI: | 10.1038/s41591-021-01590-5 |
| Popis: | Despite the success of antiretroviral therapy (ART) for people living with HIV, lifelong treatment is required and there is no cure. HIV can integrate in the host genome and persist for the life span of the infected cell. These latently infected cells are not recognized as foreign because they are largely transcriptionally silent, but contain replication-competent virus that drives resurgence of the infection once ART is stopped. With a combination of immune activators, neutralizing antibodies, and therapeutic vaccines, some nonhuman primate models have been cured, providing optimism for these approaches now being evaluated in human clinical trials. In vivo delivery of gene-editing tools to either target the virus, boost immunity or protect cells from infection, also holds promise for future HIV cure strategies. In this Review, we discuss advances related to HIV cure in the last 5 years, highlight remaining knowledge gaps and identify priority areas for research for the next 5 years. An effective and scalable cure strategy is a top priority for the HIV research field; this Review discusses recent advances, knowledge gaps, and priority research areas for the next 5 years. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink